JNJ-4178 (adafosbuvir, odalasvir, and simeprevir) in Japanese patients with chronic hepatitis C virus genotype 1 or 2 infection with or without compensated cirrhosis: the Phase IIa OMEGA-3 study.

Tetsuo TakeharaKazuaki ChayamaMasayuki KurosakiHiroshi YatsuhashiYasuhito TanakaNaoki HiramatsuNaoya SakamotoYasuhiro AsahinaAkito NozakiToshikazu NakanoYosuke HagiwaraHiroko ShimizuHiroki YoshidaYuhan HuangMichael BiermerLeen VijgenNorio Hayashi

Published in: Journal of gastroenterology (2020)

In HCV GT1- and GT2-infected Japanese patients, treatment with JNJ-4178 was well tolerated and resulted in 100% of patients achieving SVR12.

Keyphrases

hepatitis c virus
end stage renal disease
human immunodeficiency virus
ejection fraction
chronic kidney disease
newly diagnosed
peritoneal dialysis
prognostic factors
patient reported outcomes
hiv infected
smoking cessation
antiretroviral therapy